Press release
Key Trends Reshaping the GM1 Gangliosidosis Market: Strategic Partnership To Advance Gene Therapies For Rare Diseases Industry Transformation
GM1 Gangliosidosis
GM1 Gangliosidosis Market Size Growth Forecast: What to Expect by 2025?
The scope of the gm1 gangliosidosis market has seen swift expansion lately, projected to increase from its 2024 valuation of $0.51 billion to $0.57 billion by 2025, reflecting an 11.1% compound annual growth rate. This upswing during the preceding period stems from several contributing factors, including a higher incidence of individuals affected by gm1 gangliosidosis, heightened attention within the gm1 gangliosidosis domain, an escalator in rare disease recognition levels, spreading preference for research centered around the patient, and greater emphasis being placed on timely intervention strategies.
How Will the GM1 Gangliosidosis Market Size Evolve and Grow by 2029?
Forecasting significant expansion, the gm1 gangliosidosis market is projected to reach a valuation of $0.87 billion by 2029, demonstrating a robust compound annual growth rate of 11.0%; this upward trajectory is fueled by a growing incidence of gm1 gangliosidosis diagnoses, the heightened awareness surrounding lysosomal storage disorders, a surge in ongoing clinical investigations, intensified attention toward gene therapy and gene editing modalities, the expanding use of personalized and precision medicine approaches, and wider implementation of genetic screening initiatives; concurrent with this growth, key market dynamics shaping the future include breakthroughs in gene-editing methodologies, deeper integration of technology within the healare sector, improvements in diagnostic methods, the development of more sophisticated product formulations, and continued progress in genetic therapeutic strategies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
What Drivers Are Propelling the Growth of GM1 Gangliosidosis Market Forward?
Anticipated widespread uptake of gene therapy interventions is set to propel the expansion within the GM1 gangliosidosis market segment. Gene therapy, a therapeutic modality focused on modifying or substituting genes in patient cells for disease mitigation or prevention, is witnessing increased acceptance due to progress in genetic studies, better results for conditions lacking prior viable treatments, and augmenting official endorsement of novel approaches. Specifically concerning GM1 gangliosidosis, this treatment method is designed around introducing a correct version of the faulty GLB1 gene into affected cells, aiming to reestablish necessary beta-galactosidase enzyme function and subsequently curb the accumulation of harmful substances; evidence supporting this upward trend includes data from April 2024, where the American Society of Gene & Cell Therapy, a US non-profit scientific and medical entity, reported a 10% quarter-over-quarter surge in Phase III gene therapy clinical trials during the final quarter, representing the initial quarterly uptick observed since the third quarter of 2022, thereby solidifying gene therapy's role as a key driver for the growing GM1 gangliosidosis market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
Which Emerging Trends Are Transforming the GM1 Gangliosidosis Market in 2025?
Key players within the GM1 gangliosidosis sector are prioritizing strategic alliances as a means to solidify their standing in the marketplace. These collaborative arrangements are instrumental in pushing forward gene therapy innovation by pooling distinct competencies, capital, and technological platforms, thereby expediting the processes of investigation, testing in human subjects, and bringing treatments to market. As an illustration, during October 2024, a cooperative arrangement was established between GEMMA Biotherapeutics Inc., a firm situated in the United States specializing in biotechnological solutions, and the Oswaldo Cruz Foundation (Fiocruz), a prominent Brazilian entity dedicated to health investigation, specifically for advancing gene therapies targeting infrequently occurring conditions such as GM1 gangliosidosis. This accord encompasses a financial commitment reaching $100 million from Fiocruz, designated for supporting the necessary clinical studies and the scaling up of production, with the overarching goal of integrating these sophisticated medical interventions into Brazil's publicly funded medical infrastructure. Furthermore, this joint venture underlines a commitment to transferring the required knowledge and intends to broaden availability of therapies that historically have been accessible primarily only to segments of the population with greater financial means.
What Are the Key Segments in the GM1 Gangliosidosis Market?
The gm1 gangliosidosismarket covered in this report is segmented -
1) By Disease Type: Type 1 GM1 Gangliosidosis; Type 2 GMT Gangliosidosis; Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants; Bone Marrow Transplantation; Cord-Blood Hematopoietic Stem-Cell Transplantation; Enzyme Replacement; Gene Therapy
3) By End-User: Research Institutes; Hospitals; Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset; Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset; Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset; Atypical Adult Onset
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp
Who Are the Key Players Shaping the GM1 Gangliosidosis Market's Competitive Landscape?
Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
What Geographic Markets Are Powering Growth in the GM1 Gangliosidosis Market?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Trends Reshaping the GM1 Gangliosidosis Market: Strategic Partnership To Advance Gene Therapies For Rare Diseases Industry Transformation here
News-ID: 4279417 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for GM1
GM1 Gangliosidosis Market to Witness Significant Growth Driven by Gene Therapy I …
Pune, India, December 12, 2025 - The GM1 Gangliosidosis Market is set to expand rapidly as breakthroughs in gene therapy and growing governmental as well as private investments reshape the treatment landscape. GM1 gangliosidosis is a rare, inherited lysosomal storage disorder resulting from GLB1 gene mutations that cause a deficiency of β-galactosidase, leading to severe neurodegeneration. With no approved curative therapy currently available, biotech innovators are intensifying efforts to develop…
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood.
Download Full PDF Sample Copy of Market Report…
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth
Introduction
GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive.
However, the last decade has witnessed a surge in…
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction
The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant…
GM1 Gangliosidosis Treatment Market
The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:
Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.
Market Dynamics:
Drivers:
Government Investments…
GM1 Gangliosidosis Treatment Market Analysis, Status and Business Outlook 2021 t …
Dec 07, 2021 (Market Intelligence Data) --Global GM1 Gangliosidosis Treatment Market Size, Status, and Forecast 2021-2026. In-depth research accumulated to offer Latest insights about acute features of the global GM1 Gangliosidosis Treatment market. This report provides a detailed overview of key factors in the GM1 Gangliosidosis Treatment Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The impact of the COVID-19 outbreak on the industry was…
